Top

Published in:

01-10-2017 | Original Paper

Silence Surrounding Hepatitis C Status in Risk Relationships Among Rural People Who Use Drugs

Authors: Megan G. Hofmeister, Jennifer R. Havens, April M. Young

Published in: Journal of Prevention | Issue 5/2017

Abstract

Hepatitis C virus (HCV) has reached epidemic proportions in rural Central Appalachia in recent years. We sought to identify demographic, behavioral, and interpersonal characteristics associated with HCV serostatus disclosure among high risk people who use drugs (PWUD) in Appalachian Kentucky. HCV antibody-positive participants (n = 243), drawn from the fifth follow-up assessment of a longitudinal study of rural PWUD, completed interviewer-administered questionnaires eliciting demographic and interpersonal characteristics, risk behaviors, and information about HCV disclosure. We assessed correlates of HCV disclosure using gender-stratified multivariate logistic regression. Participants reported having disclosed their HCV-positive status to a current sex partner (44.0%), family member (35.8%), close friend (9.5%), or past sex partner (6.6%). Of those reporting current (n = 72) or past (n = 215) injection drug use (IDU), only 2.8% disclosed to current and 0.9% disclosed to past IDU partners, respectively. Female participants were more likely than male participants to disclose to current sex partners and family member(s). In multivariate analyses, adjusting for time since testing HCV positive, older age and lifetime history of drug treatment were associated with decreased odds of HCV disclosure among females, while only lifetime history of drug treatment was associated with decreased odds of HCV disclosure among males. In summary, the almost complete absence of disclosure to current or former injection drug use partners was concerning. However, most participants (69.1%) reported disclosing their HCV status to at least one of their social referents, suggesting that family members, partners, and friends of people living with HCV could play a critical role in encouraging uptake of treatment. Although further research is warranted, it is clear that interventions are needed to encourage HCV disclosure among those most at risk of transmitting HCV.

Alter, M. J. (2007). Epidemiology of hepatitis C virus infection. World Journal of Gastroenterology, 13(17), 2436.CrossRefPubMedPubMedCentral

Camacho-Gonzalez, A. F., Wallins, A., Toledo, L., Murray, A., Gaul, Z., Sutton, M. Y., et al. (2015). Risk factors for HIV transmission and barriers to HIV disclosure: Metropolitan Atlanta youth perspectives. AIDS Patient Care and STDs, 30(1), 18–24.CrossRefPubMed

Carruthers, S. J. (2005). Preventing hepatitis C: What do positive injectors do? Drug and Alcohol Review, 24(2), 193–198.CrossRefPubMed

Centers for Disease Control and Prevention (CDC). (2015). Surveillance for viral hepatitis—United States, 2013. Retrieved February 10, 2016, from http://www.cdc.gov/hepatitis/statistics/2013surveillance/commentary.htm#hepatitisC

Centers for Disease Control and Prevention (CDC). (2015). Viral hepatitis—Hepatitis C FAQs for health professionals. Retrieved December 9, 2015, from http://www.cdc.gov/hepatitis/hcv/hcvfaq.htm#section1

Centers for Disease Control and Prevention (CDC). (n.d.). A guide to comprehensive hepatitis C counseling and testing. Retrieved March 4, 2016, from http://www.cdc.gov/hepatitis/resources/professionals/pdfs/counselingandtesting.pdf

Crawford, S., & Bath, N. (2013). Peer support models for people with a history of injecting drug use undertaking assessment and treatment for hepatitis C virus infection. Clinical Infectious Diseases, 57(suppl 2), S75–S79.CrossRefPubMed

Crockett, B., & Gifford, S. M. (2004). “Eyes Wide Shut”: Narratives of women living with hepatitis C in Australia. Women and Health, 39(4), 117–137.CrossRefPubMed

Edlin, B. R., & Carden, M. R. (2006). Injection drug users: The overlooked core of the hepatitis C epidemic. Clinical Infectious Diseases, 42(5), 673–676.CrossRefPubMedPubMedCentral

Edlin, B. R., Eckhardt, B. J., Shu, M. A., Holmberg, S. D., & Swan, T. (2015). Toward a more accurate estimate of the prevalence of hepatitis C in the United States. Hepatology, 62(5), 1353–1363.CrossRefPubMedPubMedCentral

Emlet, C. A. (2006). A comparison of HIV stigma and disclosure patterns between older and younger adults living with HIV/AIDS. AIDS Patient Care and STDs, 20(5), 350–358.CrossRefPubMed

Fry, M., & Bates, G. (2012). The tasks of self-managing hepatitis C: The significance of disclosure. Psychology & Health, 27(4), 460–474.CrossRef

Gao, F., Talbot, E. A., Loring, C. H., Power, J. J., Dionne-Odom, J., Alroy-Preis, S., et al. (2014). Performance of the OraQuick HCV rapid antibody test for screening exposed patients in a hepatitis C outbreak investigation. Journal of Clinical Microbiology, 52(7), 2650–2652.CrossRefPubMedPubMedCentral

Grebely, J., Knight, E., Genoway, K. A., Viljoen, M., Khara, M., Elliott, D., et al. (2010). Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: A novel model incorporating multidisciplinary care and peer support. European Journal of Gastroenterology and Hepatology, 22(3), 270–277.CrossRefPubMed

Gritsenko, D., & Hughes, G. (2015). Ledipasvir/Sofosbuvir (Harvoni): Improving options for hepatitis C virus infection. Pharmacy and Therapeutics, 40(4), 256–276.PubMedPubMedCentral

Grodensky, C. A., Golin, C. E., Jones, C., Mamo, M., Dennis, A. C., Abernethy, M. G., et al. (2015). “I should know better”: The roles of relationships, spirituality, disclosure, stigma, and shame for older women living with HIV seeking support in the South. Journal of the Association of Nurses in AIDS Care, 26(1), 12–23.CrossRefPubMed

Gyarmathy, V. A., & Latkin, C. A. (2008). Individual and social factors associated with participation in treatment programs for drug users. Substance Use and Misuse, 43(12–13), 1865–1881.CrossRefPubMedPubMedCentral

Gyarmathy, V. A., Neaigus, A., Li, N., Ujhelyi, E., Caplinskiene, I., Caplinskas, S., et al. (2011). Infection disclosure in the injecting dyads of Hungarian and Lithuanian injecting drug users who self-reported being infected with hepatitis C virus or human immunodeficiency virus. Scandinavian Journal of Infectious Diseases, 43(1), 32–42.CrossRefPubMed

Hagan, H., Campbell, J., Thiede, H., Strathdee, S., Ouellet, L., Kapadia, F., et al. (2006). Self-reported hepatitis C virus antibody status and risk behavior in young injectors. Public Health Reports, 121(6), 710–719.CrossRefPubMedPubMedCentral

Hahn, J. A., Evans, J. L., Davidson, P. J., Lum, P. J., & Page, K. (2010). Hepatitis C virus risk behaviors within the partnerships of young injecting drug users. Addiction, 105(7), 1254–1264.CrossRefPubMedPubMedCentral

Havens, J. R., Lofwall, M. R., Frost, S. D. W., Oser, C. B., Leukefeld, C. G., & Crosby, R. A. (2013). Individual and network factors associated with prevalent hepatitis C infection among rural Appalachian injection drug users. American Journal of Public Health, 103(1), e44–e52.CrossRefPubMedPubMedCentral

Heckathorn, D. D. (1997). Respondent-driven sampling: A new approach to the study of hidden populations. Social Problems, 44(2), 174–199.CrossRef

Heckathorn, D. D. (2002). Respondent-driven sampling II: Deriving valid population estimates from chain-referral samples of hidden populations. Social Problems, 49(1), 11–34.CrossRef

Hopwood, M., Nakamura, T., & Treloar, C. (2010). Disclosing hepatitis C infection within everyday contexts implications for accessing support and healthcare. Journal of Health Psychology, 15(6), 811–818.CrossRefPubMed

Lehman, J. S., Carr, M. H., Nichol, A. J., Ruisanchez, A., Knight, D. W., Langford, A. E., et al. (2014). Prevalence and public health implications of state laws that criminalize potential HIV exposure in the United States. AIDS and Behavior, 18(6), 997–1006.CrossRefPubMedPubMedCentral

McCreaddie, M., Lyons, I., Horsburgh, D., Miller, M., & Frew, J. (2011). The isolating and insulating effects of hepatitis C: A substantive grounded theory. Gastroenterology Nursing, 34(1), 49–59.CrossRefPubMed

Murray, C. J., Kulkarni, S., & Ezzati, M. (2005). Eight Americas: New perspectives on U.S. health disparities. American Journal of Preventive Medicine, 29(5 Suppl 1), 4–10.CrossRefPubMed

Przybyla, S. M., Golin, C. E., Widman, L., Grodensky, C. A., Earp, J. A., & Suchindran, C. (2013). Serostatus disclosure to sexual partners among people living with HIV: Examining the roles of partner characteristics and stigma. AIDS Care, 25(5), 566–572.CrossRefPubMed

Rhodes, T., Prodanović, A., Žikić, B., Kuneski, E., Pavićević, T., Karadžić, D., et al. (2008). Trust, disruption and responsibility in accounts of injecting equipment sharing and hepatitis C risk. Health, Risk and Society, 10(3), 221–240.CrossRef

SAS Institute. (2014). Base SAS 9.4 procedures guide. SAS Institute.

Smith, B. D., Jewett, A., Burt, R. D., Zibbell, J. E., Yartel, A. K., & DiNenno, E. (2013). “To share or not to share?” Serosorting by hepatitis C status in the sharing of drug injection equipment among NHBS-IDU2 participants. Journal of Infectious Diseases, 208(12), 1934–1942.CrossRefPubMed

Sullivan, K. M. (2005). Male self-disclosure of HIV-positive serostatus to sex partners: A review of the literature. Journal of the Association of Nurses in AIDS Care, 16(6), 33–47.CrossRefPubMed

Suryaprasad, A. G., White, J. Z., Xu, F., Eichler, B.-A., Hamilton, J., Patel, A., et al. (2014). Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006–2012. Clinical Infectious Diseases, 59(10), 1411–1419.CrossRefPubMed

Sylvestre, D. L., & Zweben, J. E. (2007). Integrating HCV services for drug users: A model to improve engagement and outcomes. International Journal of Drug Policy, 18(5), 406–410.CrossRefPubMed

Temple-Smith, M., Gifford, S., & StoovÚ, M. (2004). The lived experience of men and women with hepatitis C: Implications for support needs and health information. Australian Health Review, 27(2), 46–56.CrossRefPubMed

Terrault, N. A., Dodge, J. L., Murphy, E. L., Tavis, J. E., Kiss, A., Levin, T. R., et al. (2013). Sexual transmission of hepatitis C virus among monogamous heterosexual couples: The HCV partners study. Hepatology, 57(3), 881–889.CrossRefPubMedPubMedCentral

Tshweneagae, G. T., Oss, V. M., & Mgutshini, T. (2015). Disclosure of HIV status to sexual partners by people living with HIV. Curationis, 38(1), 1–6.CrossRef

Wang, J., Falck, R. S., Li, L., Rahman, A., & Carlson, R. G. (2007). Respondent-driven sampling in the recruitment of illicit stimulant drug users in a rural setting: Findings and technical issues. Addictive Behaviors, 32(5), 924–937.CrossRefPubMed

Wozniak, L., Prakash, M., Taylor, M., & Wild, T. C. (2007). Everybody’s got it, but…: Situational and strategic participation in normalized HCV discourse among injection drug users in Edmonton. Canada. International Journal of Drug Policy, 18(5), 388–396.CrossRefPubMed

Young, A. M., Crosby, R. A., Oser, C. B., Leukefeld, C. G., Stephens, D. B., & Havens, J. R. (2012). Hepatitis C viremia and genotype distribution among a sample of nonmedical prescription drug users exposed to HCV in rural Appalachia. Journal of Medical Virology, 84(9), 1376–1387.CrossRefPubMedPubMedCentral

Young, A. M., Rudolph, A. E., Quillen, D., & Havens, J. R. (2014). Spatial, temporal and relational patterns in respondent-driven sampling: Evidence from a social network study of rural drug users. Journal of Epidemiology and Community Health, 68(8), 792–798.CrossRefPubMedPubMedCentral

Young, A. M., Stephens, D. B., Khaleel, H. A., & Havens, J. R. (2015). Hepatitis C vaccine clinical trials among people who use drugs: Potential for participation and involvement in recruitment. Contemporary Clinical Trials, 41, 9–16.CrossRefPubMed

Zack, M., Singleton, J., Satterwhite, C., Delaney, K., & Wall, K. (2011). Collinearity macro (SAS). Department of Epidemiology RSPH at Emory University (contact dkleinb@ emory. edu).

Zibbell, J. E., Iqbal, K., Patel, R. C., Suryaprasad, A., Sanders, K. J., Moore-Moravian, L., et al. (2015). Increases in hepatitis C virus infection related to injection drug use among persons aged ≤30 years-Kentucky, Tennessee, Virginia, and West Virginia, 2006–2012. Morbidity and Mortality Weekly Report, 64(17), 453–458.PubMed

Title: Silence Surrounding Hepatitis C Status in Risk Relationships Among Rural People Who Use Drugs
Authors: Megan G. Hofmeister
Jennifer R. Havens
April M. Young
Publication date: 01-10-2017
Publisher: Springer US
Published in: Journal of Prevention / Issue 5/2017
Print ISSN: 2731-5533
Electronic ISSN: 2731-5541
DOI: https://doi.org/10.1007/s10935-017-0483-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Silence Surrounding Hepatitis C Status in Risk Relationships Among Rural People Who Use Drugs

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2017

Sleep and Mental Health in the General Population of Elderly Women

Life Course Perspectives on the Onset and Continuity of Preventive Healthcare Behaviors

A Toddler Parenting Intervention in Primary Care for Caregivers With Depression Symptoms

Relationships Among Chewing Tobacco, Cigarette Smoking, and Chronic Health Conditions in Males 18–44 Years of Age

Are Negative Peer Influences Domain Specific? Examining the Influence of Peers and Parents on Externalizing and Drug Use Behaviors